The contract research organization Syneos Health didn’t hold up its end of the deal and use “commercially reasonable efforts” when setting up a trial for a biotech client, an arbitration panel found. It also determined that the client owes the CRO about $1.7 million in damages — less than half of what Syneos was asking for in payment.
FSD Pharma, which contracted Syneos to set up a Phase II trial in 2021 for one of its drug candidates dubbed FSD 210, claimed in a statement Monday that Syneos failed to enroll the expected number of patients and hit enrollment deadlines.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
"cros" - Google News
July 18, 2023 at 06:16PM
https://ift.tt/7mV1ve9
CRO Syneos Health didn't hold up its end of the deal in enrollment ... - Endpoints News
"cros" - Google News
https://ift.tt/Cr6hI1A
https://ift.tt/ZDL1JHi
Bagikan Berita Ini
0 Response to "CRO Syneos Health didn't hold up its end of the deal in enrollment ... - Endpoints News"
Post a Comment